Compare Global X Cloud Computing ETF (CLOU) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs Citius Pharmaceuticals Inc — how do they compare? Global X Cloud Computing ETF trades at $24.25, while Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M). The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CLOU | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $26.38 | $1.82 |
52-Week Low | $17.60 | $0.53 |
Market Cap | — | $14.64M |
Enterprise Value | — | $10.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU trades at $24.11, up 1.49% with a bullish technical signal from moving averages. The ETF shows strong institutional interest in cloud computing exposure but faces mixed oscillators with RSI indicating overbought conditions. Recent news highlights both opportunity in underperforming tech sectors and concerns about cloud ETF performance trends.
The outlook balances cloud computing's growth potential against valuation concerns and sector volatility. Investment opportunity lies in AI-driven cloud adoption, while risks include competitive pressures and the ETF's historical underperformance compared to broader tech indices.
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
